Karyopharm Therapeutics (KPTI) Return on Sales (2012 - 2025)

Karyopharm Therapeutics has reported Return on Sales for 14 years, with the latest figure at 0.03% in Q4 2025.

• For the quarter ending Q4 2025, Return on Sales rose 1.0% year-over-year to 0.03%; the trailing twelve-month figure through Dec 2025 stood at 0.0% (changed 0.0% YoY), and the FY2025 full-year result was 0.0%, changed 0.0% from the prior year.
• Return on Sales for Q4 2025 stood at 0.03%, up from 0.01% in the prior quarter.
• The five-year high for Return on Sales was 0.03% in Q4 2025, with the low at 0.02% in Q1 2021.
• Historically, Return on Sales has averaged 0.01% across 5 years, with a median of 0.01% in 2023.
• Annual changes were most pronounced in 2021 — Return on Sales fell 3 bps — and 2024, when it increased 3 bps.
• Karyopharm Therapeutics' Return on Sales stood at 0.01% in 2021, then sank by 311 bps to 0.01% in 2022, then retreated by 8 bps to 0.01% in 2023, then surged by 221 bps to 0.01% in 2024, then soared by 77 bps to 0.03% in 2025.
• The last three Return on Sales figures came in at 0.03% (Q4 2025), 0.01% (Q3 2025), and 0.01% (Q2 2025), per Business Quant data.